Derek DiRocco

Derek DiRocco has a diverse work experience in the field of finance and pharmaceuticals. Derek is currently a Partner at RA Capital Management, L.P., where they have held various roles since joining in 2013, including Principal, Analyst, and Associate. Derek is also currently a Director at Mineralys Therapeutics, Inc., Acrivon Therapeutics, Inc., Rivus Pharmaceuticals, and Werewolf Therapeutics. Derek serves as a Board Observer at Carmot Therapeutics, Inc., Frontier Medicines, and Vaxcyte. Previously, they held the position of Director at iTeos Therapeutics SA and 89bio. Overall, Derek has demonstrated their expertise and leadership in the financial and pharmaceutical industries through their various roles and responsibilities.

Derek DiRocco's education history consists of completing a Bachelor of Arts degree in Biology from the College of the Holy Cross from 1998 to 2002. Subsequently, they pursued a PhD in Pharmacology from the University of Washington - School of Medicine from 2004 to 2009.